PD-L1-expressing Regulatory T Cells in Blood and Urine of Localized Prostate Cancer Patients Undergoing Iodine-125 Permanent Brachytherapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Xuanwu Hospital, Beijing
- Enrollment
- 20
- Primary Endpoint
- the level of PD-L1-expressing regulatory T cells in blood and urine
- Last Updated
- 6 years ago
Overview
Brief Summary
Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer is poorly responsive to immune checkpoint inhibition. The combination of immunotherapy and radiotherapy is an emerging clinical treatment aradigm. X-ray radiation treatment can activate both the adaptive and innate immune systems through directly killing tumor cells, causing mutations in tumor-derived peptides, and causing localized inflammation that increases immune cell trafficking to tumors. Recently, preclinical study reported that immune checkpoint inhibition combined with radiotherapy treats CPRC with significant increases in median survival compared to drug alone.
Detailed Description
Permanent brachytherapy is one of those standard treatments for localized prostate cancer patients. Biopsy confirms prostate cancer. Blood and urine of localized prostate cancer patients will be collected before and at different time points after permanent brachytherapy (1, 3, 6, and 12 months)
Investigators
ou tongwen
chairman of urology
Xuanwu Hospital, Beijing
Eligibility Criteria
Inclusion Criteria
- •Biopsy confirms prostate cancer
- •Localized Prostate Cancer, ≤cT3
- •No chemotherapy or Hormonal therapy before Permanent Brachytherapy
Exclusion Criteria
- •Unacceptable operative risk
- •Poor anatomy which in the opinion of the radiation oncologist could lead to a suboptimal implant (e.g.,large or poorly healed transurethral resection of the prostate (TURP) defect, large median lobe, large gland size).
- •Pathologically positive lymph nodes
- •Significant obstructive uropathy
- •Distant metastases
- •Use steroids regularly
- •The diagnosis was accompanied by immune-related diseases
- •Allergic constitution
- •Abnormal white blood cell and lymphocyte counts
- •Ever underwent other treatments for prostate cancer, such as chemotherapy or Hormonal therapy
Outcomes
Primary Outcomes
the level of PD-L1-expressing regulatory T cells in blood and urine
Time Frame: 2 year
the level of PD-L1-expressing regulatory T cells in blood and urine